United States - English - NLM (National Library of Medicine)

professional complementary health formulas - alternaria 30x, 60x, 100x aspergillus niger 30x, 60x, 100x candida albicans 30x, 60x, 100x candida torresii 30x, 60x, 100x candida tropicalis 30x, 60x, 100x cryptococcus 30x, 60x, 100x geotrichum candidum 30x, 60x, 100x mucor racemosus 30x, 60x, 100x penicillium notatum 30x, 60x, 100x pullularia pullulans 30x, 60x, 100x rhizopus nigricans 30x, 60x, 100x - for the temporary relief of runny nose, sneezing, itching of the nose or throat, itchy or watery eyes, headache, chills, or irritated, red, or itchy skin.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

United States - English - NLM (National Library of Medicine)

allermed laboratories, inc. - mucor plumbeus (unii: d7401pwy6e) (mucor plumbeus - unii:d7401pwy6e) - mucor plumbeus 0.1 g in 1 ml - allergenic extract may be used as a diagnostic skin test reagent in persons suspected of being sensitive to the allergenic source material from which the extract is made. skin tests should be used in conjunction with a thorough allergic history to establish the relevance of a given allergen in the etiology of allergic disease. 4,5,6 immunotherapy with allergenic extract is indicated in persons suffering from allergic rhinitis, bronchitis, conjunctivitis, urticaria and asthma. the therapeutic efficacy of allergenic extract has been proven in ragweed, grass, and mountain cedar pollinosis, cat-induced asthma and hypersensitivity to hymenoptera venoms. 7-12 immunotherapy may be used along with or exclusive of antihistamines and other medications used to control allergic symptoms. allergenic extract should not be administered to a non-allergic person. however, there are no absolute contraindications to the use of allergenic extract for treatment in appropriate individuals. relative contraindications in

United States - English - NLM (National Library of Medicine)

syntrion gmbh - mucor racemosus 6x 10% -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

inmunotek - mucor mucedo allergen extract - solution for skin-prick test

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - mucor racemosus, quantity: 1 ml/ml (equivalent: mucor racemosus, qty 100 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

United States - English - NLM (National Library of Medicine)

energique, inc. - arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), phosphorus (unii: 27ylu75u4w) (phosphorus - unii:27ylu75u4w), pulsatilla vulgaris (unii: i76kb35jev) (pulsatilla vulgaris - unii:i76kb35jev), sepia officinalis juice (unii: qdl83wn8c2) (sepia officinalis juice - unii:qdl83wn8c2), alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), rhizopus stolonifer - may temporarily relieve symptoms associated with mold allergies, such as runny nose.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. may temporarily relieve symptoms associated with mold allergies, such as runny nose.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 6 [hp_x] in 1 ml

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

steriline sdn. bhd. - promethazine hydrochloride; carbocisteine -

United States - English - NLM (National Library of Medicine)

jubilant hollisterstier llc - bos taurus hair (unii: toq97z8644) (bos taurus hair - unii:toq97z8644), bos taurus dander (unii: c8vys726o8) (bos taurus dander - unii:c8vys726o8) - equus caballus hair 0.01 g in 1 ml - non-standardized allergenic extracts are indicated for: - skin test diagnosis of individuals with a clinical history of allergy to the specific corresponding allergens. non-standardized allergenic extracts are indicated for: - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for allergen specific ige antibodies for the specific corresponding allergens. non-standardized allergenic extracts are contraindicated in individuals with the following conditions: - severe, unstable or uncontrolled asthma. - history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment. - medical conditions that reduce the ability to survive anaphylaxis. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti

United States - English - NLM (National Library of Medicine)

jubilant hollisterstier llc - yeast (unii: 3ny3sm6b8u) (yeast - unii:3ny3sm6b8u) - equus caballus hair 0.01 g in 1 ml - non-standardized allergenic extracts are indicated for: - skin test diagnosis of individuals with a clinical history of allergy to the specific corresponding allergens. non-standardized allergenic extracts are indicated for: - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for allergen specific ige antibodies for the specific corresponding allergens. non-standardized allergenic extracts are contraindicated in individuals with the following conditions: - severe, unstable or uncontrolled asthma. - history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment. - medical conditions that reduce the ability to survive anaphylaxis. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti